Abstract
In the endeavour to develop a model for studying gene therapy of cancers associated with human papillomaviruses (HPVs), mouse cells were transformed with the HPV type 16 (HPV16) and activated H-ras oncogenes. This was done by contransfection of plasmid p16HHMo, carrying the HPV16 E6/E7 oncogenes, and plasmid pEJ6.6, carrying the gene coding for human H-ras oncoprotein activated by G12V mutation, into secondary C57BL/6 mouse kidney cells. An oncogenic cell line, designated MK16/1/IIIABC, was derived. The epithelial origin of the cells was confirmed by their expression of cytokeratins. No MHC class I and class II molecules were detected on the surface of MK16/1/IIIABC cells. Spontaneous metastases were observed in lymphatic nodes and lungs after prolonged growth of MK16/1/IIIABC-induced subcutaneous tumours. Lethally irradiated MK16/1/IIIABC cells induced protection against challenge with 105 homologous cells, but not against a higher cell dose (5 × 105). Plasmids p16HHMo and pEJ6.6 were also used for preventive immunization of mice. In comparison with a control group injected with pBR322, they exhibited moderate protection, in terms of prolonged survival, against MK16/1/IIIABC challenge (P < 0.03). These data suggest that MK16/1/IIIABC cells may serve as a model for studying immune reactions against HPV16-associated human tumours. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA and Howley PM (1987) Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 61: 962–971
Bartek J, Vojtesek B, Staskova Z, Bartkova J, Kerekes Z, Rejthar A and Kovarik J (1991) A series of 14 new monoclonal antibodies to keratins: characterization and value in diagnostic histopathology. J Pathol 164: 215–224
Bartkova J, Bartek J, Lukas Z, Vojtesek B, Staskova Z, Bursova H, Pavlovska R, Rejthar A and Kovarik J (1991) Effects of tissue fixation conditions and protease pretreatment on immunohistochemical performance of a large series of new anti-keratin monoclonal antibodies: value in oncopathology. Neoplasma 38: 439–446
Blin N and Stafford DW (1976) A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 3: 2303–2308
Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R and Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796–802
Bubeník J, Simová J, Vondrys P, Vonka R, Kitasato H, Bostík P and Vonka V (1996) IL-2 as adjuvant for vaccination with cells malignantly converted by HPV 16 or 3-MC. Int J Oncol 8: 477–481
Bubeník J, Simova J, Hajkova R, Sobota V, Jandlova T, Smahel M, Sobotkova E and Vonka V (1999) Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int J Oncol 14: 593–597
Chen LP, Thomas EK, Hu SL, Hellstrom I and Hellstrom KE (1991) Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 88: 110–114
Chen L, Mizuno MT, Singhal MC, Hu SL, Galloway DA, Hellstrom I and Hellstrom KE (1992) Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 148: 2617–2621
Chomczynski P (1993) A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15: 532–537
Colbere-Garapin F, Horodniceanu F, Kourilsky P and Garapin AC (1981) A new dominant hybrid selective marker for higher eukaryotic cells. J Mol Biol 150: 1–14
Connor ME, Davidson SE, Stern PL, Arrand JR and West CML (1993) Evaluation of multiple biological parameters in cervical carcinoma: high macrophage infiltration in HPV-associated tumours. Int J Gynecol Cancer 3: 103–109
Cromme FV, van-Bommel PF, Walboomers JM, Gallee MP, Stern PL, Kenemans P, Helmerhorst TJ, Stukart MJ and Meijer CJ (1994) Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 69: 1176–1181
Galloway DA and McDougall JK (1996) The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Semin Cancer Biol 7: 309–315
Hung K, Hayashi R, Lafond WA, Lowenstein C, Pardoll D and Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188: 2357–2368
Jochmus I, Schafer K, Faath S, Muller M and Gissmann L (1999) Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 30: 269–274
Keating PJ, Cromme FV, Duggan KM, Snijders PJ, Walboomers JM, Hunter RD, Dyer PA and Stern PL (1995) Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 72: 405–411
Kitasato H, Vonka R, Bostik P, Hamsikova E, Sobotkova E, Smahel M and Vonka V (1996) Properties of Syrian hamster cells transformed by human papillomavirus type 16. Acta Virol 40: 281–288
Kutinová L (1975) Growth of SV 40, adeno 7 and SV 40-adeno 7 viruses in monkey and human cells at 29 degrees and 37 degrees C. Arch Virol 47: 257–268
Kutinová L and Vonka V (1978) Determination of virus-specific antigens in extracts from herpes simplex virus-infected cells by a 51Cr release inhibition test. Inf Immun 20: 587–591
Lauerova L, Kovarik J, Bartek J, Rejthar A and Vojtesek B (1988) Novel monoclonal antibodies defining epitope of human cytokeratin 18 molecule. Hybridoma 7: 495–504
Lin KY, Guarnieri FG, Staveley OK, Levitsky HI, August JT, Pardoll DM and Wu TC (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21–26
Liu Z, Ghai J, Ostrow RS and Faras AJ (1995) The expression levels of the human papillomavirus type 16 E7 correlate with its transforming potential. Virology 207: 260–270
McNeil C (1997a) HPV vaccine treatment trials proliferate, diversify. J Natl Cancer Inst 89: 280–281
McNeil C (1997b) HPV vaccines for cervical cancer move toward clinic, encounter social issues. J Natl Cancer Inst 89: 1664–1666
Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD and Schreiber H (1999) CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 96: 8633–8638
Parkin DM, Pisani P and Ferlay J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54: 594–606
Shih C and Weinberg RA (1982) Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29: 161–169
Smahel M, Sobotkova E, Vonka V, Hamsikova E, Zak R, Kitasato H and Ludvikova V (1999) DNA vaccine against oncogenic hamster cells transformed by HPV16 E6/E7 oncogenes and the activated ras oncogene. Oncol Rep 6: 211–215
Sobotková E, Indrova M, Simova J, Bubenik J and Vonka V (1996) Cross-reactivity of murine and hamster IL-2 mitogenic signal. Immunol Lett 50: 115–117
Trujillo JM and Mounts P (1996) Transforming activity of the E6 gene of HPV-11gt in NIH 3T3 and REF 52 cells: correlation with the level of E6 transcription. Virology 220: 1–9
van Driel WJ, Kenter GG, Fleuren GJ, Melief CJ and Trimbos BJ (1999) Immunotherapeutic strategies for cervical squamous carcinoma. Hematol Oncol Clin North Am 13: 259–273
Vonka V (1996) Human papillomavirus vaccines. Folia Biol Praha 42: 73–78
Vonka V, Sobotkova E, Hamsikova E, Smahel M, Zak R, Kitasato H and Sainerova H (1998) Induction of anti-tumour immunity by suicide-gene-modified HPV-16-transformed hamster cells. Int J Cancer 77: 470–475
Vousden KH, Doniger J, DiPaolo JA and Lowy DR (1988) The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res 3: 167–175
zur Hausen H (1996) Viruses in human tumors – reminiscences and perspectives. Adv Cancer Res 68: 1–22
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Šmahel, M., Sobotková, E., Bubeník, J. et al. Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br J Cancer 84, 374–380 (2001). https://doi.org/10.1054/bjoc.2000.1615
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1615